importantly, by alterations of downstream molecular expression and function [5] . Cancer develops through steps of initiation, promotion, progression, and metastasis. The initial step is commonly attributed to genetic changes that may be spontaneous or triggered by carcinogens. Cells gradually become malignant through a progressive series of alternations such that they lose their normally regulated functional abilities and undergo uncontrolled growth and proliferation [6, 7] . Eventually, cancer cells invade nearby tissues or migrate to distant tissue via circulatory systems, leading to metastasis.
Cancer development is accompanied by changes in the molecular makeup of the cancer cells and their surrounding stroma. In particular, proteins may exhibit a range of variations in expression quantities, posttranslational modifications, folding, biologic half-lives, or degradation pathways. In early stages of cancer evolution, the immune surveillance system has the ability to recognize nascent cancer cells and to develop cellular or humoral immunological responses. Antibodies against a number of tumor-associated antigens have been detected in early stages of various types of cancer [8] [9] [10] [11] [12] . For example, anti-p53 and anti-p16 were detected in 10-20% of patients with various types of cancer [9, 12] . Anti-p62 was positive in 21% of patients with liver cancer [13] . An autoantibody response to p90/CIP2A was detected in breast cancer [14] . These antibodies are generally absent in healthy individuals, but are persistent and stable in sera of cancer patients.
As cancer progresses, tumor cell variants that are poorly immunogenic or even immunosuppressive prevail, which can elude the immune system and evade recognition and destruction by the immune defense. Consequently, these cells can survive and grow within an immunecompetent environment. Moreover, cancer cells can actively suppress immune responses by different pathways [6, 15] . Hence, when designing effective immunotherapies, it is crucial to distinguish cancer-associated molecules that are able (immunogenic) vs. unable (non-immunogenic) to evoke immune responses.
In this study, we focused on discovering overexpressed immunogenic proteins in colon cancer tissue that are able to induce circulating antibody production in patients. We developed a serum antibody screening method to identify these molecules. We used the cancer patients' own sera as the primary antibody source to screen for differential protein reactivity in autologous matched normal and cancerous tissue pairs. We identified and then validated a number of immunogenic proteins as potential markers for colon cancer.
RESULTS

Differential protein expression profiles in cancer and normal tissue
Matched pairs of normal and cancerous colon tissues were obtained from patients undergoing surgical colectomy procedures. For patients whose colon cancer had metastasized to the liver, tissue samples from the liver metastases were also obtained. The tissue protein extraction procedure was optimized, and proteins were extracted from all matched tissue pairs or sets in parallel with the optimized protocol. Extracted proteins were initially assessed by 1D SDS PAGE and then separated and analyzed by 2D gel electrophoresis. From proteins extracted from each tissue sample, triplicates of high quality 2D gels were prepared: one gel was used for sequencing of differentially expressed proteins by mass spectrometry (Figures 1-2 , top row), another for detection of reactivities with standard autoantibody control serum by 2D Western blotting (Figures 1-2 , middle row), and a third for discovery of reactivities with the cancer patient's own serum (Figures 1-2 , bottom row).
From each tissue extract, more than 500 distinct protein spots were typically detectable on 2D gels (Figures 1A-1B, 2A-2C). By computational gel image comparison, on average about 80 protein spots were found to be differentially expressed between normal and tumor tissue, when spots exhibiting at least 2-fold intensity changes were considered. When sequenced by mass spectrometry, each spot on the 2D protein gels often yielded tens to hundreds of protein identities. Therefore, the number of protein identities is enormous if no further selection criterion is applied. We then decided to narrow our focus to proteins that are immunogenic in cancer tissue, i.e., proteins in cancer tissue that are capable of inducing the production of specific serum antibodies in the patient.
Cancer-specific antibodies and protein immunogens
In order to identify cancer-specific immunogen markers, proteins extracted from the tumor tissue and its matching normal tissue were interrogated with the patient's own serum by 2D Western blotting ( Figures  1-2 , bottom row). To further distinguish tumor-specific immunogens vs. tumor non-specific autoantigens that react with common or naturally occurring autoantibodies, the proteins from tissue extracts were also probed with control sera containing high titers of autoantibodies from unrelated non-oncologic autoimmune disease patients (Figures 1-2 , middle row).
For the initial discovery stage, specimens from 2 patients, a male with stage II (pT3 pN0) colon adenocarcinoma ( Figure 1 ) and a female with stage IV (pT3 pN2b pM1a) colon adenocarcinoma and liver metastases (Figure 2 ), were examined in depth. We purposely chose two patients who differed with regard to gender and cancer stage hypothesizing that common markers that were shared between their tumors might be applicable to a wider spectrum of colon adenocarcinoma cases. Shared markers identified from these two patients www.impactjournals.com/oncotarget were further examined in a larger cohort of patients as presented later in the paper.
Results from the stage II male colon cancer patient are shown in Figure 1 . When blotted with control autoantibodies, 15 reactive spots appeared against proteins from normal colonic mucosa ( Figure 1C ) whereas 27 reactive spots appeared against proteins from cancerous tissue ( Figure 1D ). Proteins extracted from cancer reacted more strongly with the control autoantibodies. However, overall autoantibody-reactive blotting patterns from proteins extracted from normal vs. cancer tissue appear to be similar ( Figures 1C vs. 1D ), suggesting that autoimmune autoantigens present in normal and cancerous tissue are similar or, in other words, not cancer-specific.
In contrast, when protein extracts were blotted with the cancer patient's own serum, the antibodyreactive profiles were drastically different ( Figure 1E-1F ). There were about 8 horizontal molecular weight zones comprising 32 distinct spots that reacted strongly with antibodies in the patient's serum ( Figure 1F ).
Figure 1:
Detection of antibody-reactive proteins in colon tissue extracts from a male patient with stage II colon adenocarcinoma. Proteins extracted from the normal colon tissue (CN1) and the tumor colon (CA1) portions were separated in 2D gels (A-B), blotted with a control serum containing high-titer autoantibodies to reveal cancer non-specific autoantigens found in autoimmune diseases (C-D), and blotted with serum from the cancer patient to uncover cancer-specific immunogens that induced antibodies in the serum (E-F). Note that only proteins extracted from the tumor tissue (F) showed reactivity with antibodies in the patient serum. Strikingly, no reaction was detected between serum antibodies and benign mucosal proteins ( Figure 1E ). Furthermore, comparing the blots of Figure 1D vs. 1F, it is evident that cancer-specific immunogens in colon cancer tissue ( Figure 1F ) are significantly different from autoantigens of autoimmunity ( Figure 1D ). Therefore, the patient produced serum antibodies that are specifically directed against certain proteins in his colon cancer. The findings have three implications: (i) the cancer patient developed cancer-specific antibodies that are different from commonly occurring autoantibodies, (ii) the cancerspecific antibodies recognize a small number of proteins expressed by the cancer tissue only, (iii) these antibodyreactive proteins are either absent or different in normal tissue.
Presence of colon cancer-specific immunogens in liver metastases
Results from a female patient with stage IV colon cancer and liver metastases are shown in Figure 2 . Proteins were extracted from normal and cancerous colon tissues as well as the metastatic cancer tissue and separated in 2D gels. After blotting with control serum that contained high titers of autoantibodies from an autoimmune disease patient, 1 horizontal zone of about 10 reactive spots was detected from benign colonic mucosal proteins ( Figure  2D ), while 3 horizontal zones of reactive spots were detected from colon cancer tissue proteins ( Figure 2E ). The cancerous tissue metastatic to the liver yielded about 36 spots reactive with autoimmune control serum ( Figure  2F ). Comparison of Figures 1C-1D and 2D-2F shows that, although there is some resemblance, autoantigen patterns in the two patients are largely different and not cancerspecific.
In contrast, when proteins from normal and cancer tissue were blotted with the colon cancer patient's own serum, strong reactions were detected against a number of proteins from the primary colon cancer and cancer metastatic to the liver ( Figure 2H -2I), while no reaction was detectable against proteins from normal colonic mucosa ( Figure 2G ). These observations are similar to (C: LM2) were analyzed by 2D electrophoresis. Protein extracts were blotted with a control serum containing high-titer autoantibodies from an autoimmune disease patient to exclude autoantigens non-specific to the cancer patient (D-F). Cancer-specific proteins that induced serum antibodies were revealed by blotting with serum from the cancer patient (G-I). Note that cancer-specific immunogen-antibody reactivity patterns in colon tumor (H) and liver metastatic tissue (I) appear similar. the findings from the stage II male colon cancer patient above. Strikingly, the reactivity patterns of primary cancer and metastasis resemble each other, suggesting that shared cancer-specific immunogens are expressed in both the primary and the metastasis. Thus metastatic tumor cells appear to maintain the same or similar immunogenic protein makeup compared to the primary.
The similarity of cancer-immunoreactive signatures ( Figures 1F, 2H, 2I ) from our 2 patients with different stages of colon adenocarcinoma suggested that there were at least some protein reactivities that were shared between both patients. The identification of these shared immunogens was our next focus.
Protein identification by mass spectrometry
Protein spots reacting with cancer serum antibodies were cut from 2D gels, digested with trypsin, and sequenced by mass spectrometry (MS). Protein identities were accepted only if more than two peptides in the sequence were confirmed. Proteins identified from the cancer tissue were compared with those from the matched normal mucosa. After proteins that were found in both the normal and cancer tissue were eliminated, 170 proteins were found in cancer tissues only (Table 1) .
We mapped these proteins using pathway analysis tools [10] . The 170 proteins mapped to a wide array of pathways, e.g., p53, Wnt, PI3K, apoptosis signaling, cadherin signaling, EGF receptor signaling, FGF signaling, FAS signaling, or the RAS pathway. For example, maspin and DAI1 are involved in the p53 pathway; GBB1 is involved in the Wnt and PI3K pathway; 1433G is involved in EGF receptor signaling and FGF signaling pathways; HSP7C, XIAP, FUBP1, RASF3, and PCBP1 are involved in cell apoptosis processes; and HSP7C, PCOC1, CFAD, HPT, FHR1, IN35, C1QB, PRDX1, and CL1C3 are involved in immune responses.
Among the 170 serum-reactive proteins, 4 were reproducibly detected in samples from both cancer patients, including the colon cancer tissue from both patients and the liver metastatic tissue from the patient with liver metastasis. They are maspin (mammary serine protease inhibitor), annexin A3 (ANXA3), leucine aminopeptidase 3 (LAP3), and proteasome subunit alpha type 1 (PSMA1). Because of their reproducibility, these 4 proteins were investigated further in greater depth.
Validation of maspin, LAP3, ANXA3, and PSMA1 expression by Western blotting
We first examined the differential expression levels of maspin, ANXA3, LAP3, and PSMA1 in normal colonic mucosa vs. colon adenocarcinoma by 1D Western blotting ( Figure 3 ). Fresh tissues were obtained from a validation set of 8 patients (Table 2) . Colonic adenocarcinoma tissue and adjacent normal mucosa were dissected, and proteins were extracted from both. Protein extracts were separated in 2D gels and transferred to PVDF membranes. Protein expression of maspin, LAP3, ANXA3, and PSMA1 was detected with antibodies specific against each individual protein. As shown in Figure 3 , the bands detected by Western blotting were at 42 kDa for maspin, 56 kDa for LAP3, 36 kDa for ANXA3, and 30 kDa for PSMA1. The β-actin-normalized relative protein expression ratio ER>1, =1, or <1 represents increased, unchanged, or decreased expression in cancer relative to matched benign mucosa, respectively.
Overall, expression of maspin, ANXA3, LAP3, and PSMA1 was increased in colon cancer tissue extracts. In 7 of 8 cases, maspin displayed much higher levels of protein expression in colon cancer ( Figure 3 
Validation of maspin, LAP3, ANXA3, and PSMA1 expression by IHC
The initial proteomic experiments and the Western blot follow-up in an independent cohort both indicated differential expression of these 4 proteins between normal and cancer. Next, we investigated how these potential markers are distributed at tissue and cellular levels. To this end, we used immunohistochemistry to examine maspin, ANXA3, LAP3, and PSMA1 protein tissue distribution in these 8 patients.
Maspin expression was significantly increased in primary colon carcinoma but barely detectable in matched normal colonic mucosa ( Figure 4A-4D ). 5 colon cancers showed strong expression of maspin and 3 showed medium level expression. In contrast, in the 8 matched normal mucosal tissues, maspin expression was negative in 6 and weak in 2. As assessed by semi-quantitative scoring of the immunostaining, the average score for maspin expression was 2.6 in colon cancer tissues and 0.1 in normal colon tissues ( Figure 8 ).
Maspin protein was mainly found expressed in the neoplastic colon cancer cells ( Figure 4A-4D) , both in the cytoplasm and nuclei. Poorly differentiated cancer cells showed stronger nuclear staining of maspin than well or moderately differentiated cancer cells. Strongly expressed nuclear maspin was also detectable in tumor cells at the tumor's invasive front. Maspin staining was generally negative in normal colonic mucosa, with few epithelial cells showing weak staining ( Figure 4A -4D). Overexpression of maspin was evident in an early stage I patient ( Figure 4A ), suggesting that maspin overexpression can occur early. ANXA3 was detected in the colon cancer tissues of all 8 patients, although the overall expression levels were of weak to medium intensities and predominantly cytoplasmic ( Figure 5A-5D ). In all 8 normal mucosal tissues, ANXA3 expression was absent or barely detectable. Although its expression in cancer tissue was not particularly strong, ANXA3 did increase an average 1.2-fold in cancer tissue relative to the normal counterpart as assessed by semi-quantitative assessment (Figure 8 ).
The ANXA3 expression increase appeared to remain at similar levels with no further increase in advanced stages ( Figure 5C-5D ).
LAP3 expression was present in both normal and colon cancer tissue ( Figure 6) . Among the 8 patients tested, all colon cancer tissue displayed strong expression of LAP3. LAP3 was present in colon cancer cells as well as the surrounding stroma. LAP3 was also found in lymphocyte infiltrates. LAP3 expression was visibly increased in colon cancer tissue ( Figure 6A-6D ) when compared with normal colonic mucosa. Semi-quantitative assessment of LAP3 expression revealed an average score of 3 for colon cancer tissues and 1.5 for normal colonic mucosa. PSMA1 expression was markedly increased in colon cancer tissue, although it was also detectable in normal colonic mucosa (Figure 7 ). All 8 colon cancer tissue showed strong immunoreactivity with PSMA1. Both nuclear and cytoplasm showed strong labeling. Semiquantitative assessment of PSMA1 expression yielded an average score of 3 for colon cancer and 1.7 for normal colonic mucosa (Figure 8 ). 
DISCUSSION
In this study, we focused on discovering abnormally immunogenic proteins in colon cancer that induced circulating antibodies in the patient's own serum. We were motivated by the hypothesis that cancer-specific immunogenic molecules are promising markers for cancer diagnosis as well as immunotherapeutic development.
Cancer development is dictated by progressive changes in the molecular makeup of cancer cells and the surrounding tissue milieu. While most of the molecular changes may be subtle deviations from the norm and regarded as harmless by the immune surveillance, cancer-specific changes that trigger a humoral immune responses may hold significant clues towards understanding the intricate interactions between cancer and the immune defense. We developed an immuno-proteomic strategy by combining 2D serum antibody-capture with state-of-theart proteomics methods. Using a discovery set, about 80 protein spots were found to be expressed differentially between normal colonic mucosa and cancer. Upon sequencing these spots by mass spectrometry, 170 proteins were identified in tumor tissue only but were not found in matched normal mucosa (Table 1) . Of these, maspin, ANXA3, LAP3, and PSMA1 were reproducibly discovered as serum-reactive in all 3 initially tested cancer samples, including colon tumor tissue from the 2 patients and the liver metastatic tissue from the patient with primary colon cancer and secondary liver metastasis. These proteins were hence examined in greater detail. Overexpression of these 4 proteins in cancer relative to normal was then independently confirmed by Western blotting and immunohistochemistry in a validation set of 8 patients spanning various clinical stages of colon cancer.
To our knowledge, this study is the first to report PSMA1 overexpression in colorectal cancer. PSMA1 has been reported to be overexpressed in breast cancer [17] , and PSMA1 gene expression levels have been reported to be upregulated in a neuroendocrine pulmonary tumor animal model [18] . PSMA1 (proteasome subunit alpha 1) is one of the 17 essential subunits of the 20S proteasome, a multi-catalytic proteinase complex with a highly ordered ring-shaped core structure. Another member of the proteasome, PSB7 (proteasome subunit beta 7), has previously been reported by our group to be up-regulated in colorectal cancer as a potential mechanism for immune escape [11] .
To our knowledge, our present study is also the first to report LAP3 overexpression in colorectal cancer. LAP3 (leucine aminopeptidase 3) belongs to the aminopeptidase family that comprises enzymes that catalyze the hydrolysis of leucine residues at the N-terminus of peptides and proteins [19] . LAP3 is presumably involved in the processing and regular turnover of intracellular proteins. Our Western blot and IHC results showed that LAP3 protein was much more abundant in the cancerous cells compared to matched normal colonic mucosa. Dysregulation of LAP3 expression could alter peptide activation, thus leading to changes of cell proliferation, invasion, and angiogenesis [20, 21] . Studies have shown that LAP3 is overexpressed in several malignant tumors, including ovarian epithelial malignancy, gliomas, esophageal squamous cell carcinoma, and hepatocellular carcinoma [21] [22] [23] [24] .
ANXA3 expression has been previously observed to correlate significantly with tumor growth and poor prognosis in colorectal cancer [25, 26] . However, cancer autoantigenic properties of ANXA3 have not previously been described. ANXA3 is a member of the annexin family, which binds membrane phospholipids in a calcium-dependent manner and plays a role in the regulation of cellular growth and in signal transduction pathways. ANXA3 participates in multiple biological activities, including cell apoptosis, cell proliferation, cell differentiation, signal transduction, anti-inflammatory response, endocytosis and exocytosis, which may contribute to cancer development and metastasis [25, 27] . Upregulation of ANXA3 was also found in prostate, lung, gastric, and hepatocellular cancers [27, 28] . ANXA3 expression was strongly associated with tumor size, stage, and poor prognosis [27] . ANXA3 correlates also with cell proliferation as indicated by Ki-67 and Bcl-2 expression [27] and appears to be preferentially expressed in cancer stem-like cells/cancer initiating cells (CSCs/CICs) [28] .
Maspin as a protein marker for colorectal cancer has been examined by several studies [29] [30] [31] [32] . However, maspin's cancer immunogenic property, as described in our study, has not previously been reported. Maspin expression has also been observed to be upregulated in pancreatic, gallbladder, and thyroid cancers [33] [34] [35] but down-regulated in breast, prostate, and gastric cancers and melanomas [33] [34] [35] . Maspin was identified as a marker of serrated colorectal polyps [36] . Nuclear maspin expression was reported to correlate with tumor aggressiveness in colorectal cancer [37] and may be a predictive marker for fluorouracil treatment response in colon cancer [38] .
Maspin was also reported as a CEA-interacting marker for colon cancer [39] and a marker for early recurrence in stage III and IV colon cancers [40] . Some studies claimed that subcellular localization of maspin expression in cytoplasm or nucleus correlates with colon cancer aggressiveness and treatment outcome [41, 42] . A large clinical study however reported that maspin expression was correlated with few other conventional histopathology variables and was not a significant prognostic factor in advanced stage disease [43] . Overall, the role of abundance of maspin expression in colon cancer remains currently not well defined. In so far, our discovery of a serum immunogenic property of maspin may point to another parameter that can be examined beyond simple abundance changes of the protein in the tumor.
MATERIALS AND METHODS
Clinical tissue and serum collection
All specimens used in this study were collected by the BioSpecimen Science Program at the University Health Network (UHN), Toronto, ON, Canada, according to institutional consent and IRB protocols. Samples were obtained from patients diagnosed with various stages of colonic adenocarcinoma (Table 2 ). Matched sets of specimens were collected from each patient, including primary carcinoma tissue and adjacent normal colonic mucosa, metastatic tissue (where applicable), and serum. Fresh tissues were dissected immediately after surgical removal from patients, flash frozen in liquid nitrogen, and stored at −80°C. Portions of tissues were also fixed in formalin and embedded in paraffin. Serum samples were stored at 4°C. Samples from patients 1 and 2 were used in the initial discovery studies, and further validation studies were conducted with samples from all 8 patients.
Protein extraction
Aliquots of ~200 mg of tissue were suspended in 1 mL of a protein extraction solution containing 0.15 M NaCl, 50 mM Tris-HCl (pH 7.4), 1.0% NP-40, and Complete Mini Protease Inhibitor Cocktail (Roche Diagnostics). Tissue samples were mechanically homogenized on ice and then sonicated with 10 sec on/10 sec off for 10 cycles at 4°C. The homogenates were centrifuged at 14,000 rpm in a bench top centrifuge at 4°C for 60 min. The supernatants were filtered through 0.45-μm syringe filters. The filtrates containing total soluble proteins were used for 1D and 2D gel electrophoresis analyses. Protein concentrations were measured with the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific) with bovine serum albumin (BSA) as the standard. All extracted protein samples were stored at −80°C until further analysis. www.impactjournals.com/oncotarget
1D and 2D gel electrophoresis
One dimensional (1D) SDS-PAGE analysis was performed with a SureLock Xcell system (Thermo Fisher Scientific). Protein samples were mixed with 25% NuPAGE Sample Buffer and 10% Reducing Agent and heated at 70°C for 10 min. About 20 μg of proteins were loaded into wells of 4%-12% acrylamide NuPAGE Bis-Tris gels. The proteins were separated at 200 V for 35 mins in MES SDS running buffer. Gels were stained with Bio-Safe Coomassie Blue G250 and scanned in a ChemDoc MP imaging system (Bio-Rad).
For 2D gel electrophoresis, 200-μg samples of proteins were first cleaned with the ReadyPrep 2D Cleanup Kit (Bio-Rad) or by precipitation with acetone and then dissolved in 185 μL of ReadyPrep rehydration buffer. Proteins were separated first by isoelectric focusing in 11-cm IPG (immobilized pH gradient) strips (pH 3 to 10; BioRad). Proteins were then separated in the second dimension by SDS PAGE with 8-16% gradient Criterion Tris-glycine polyacrylamide gels and Tris-glycine SDS buffer (BioRad). Gels were stained with Bio-Safe Coomassie Blue G250 and scanned in a ChemDoc MP imaging system.
Protein sequencing by LC-MS
Protein spots of interest were manually excised from 2D gels and fragmented by in-gel tryptic digestion. In brief, the gel spots were washed with 50 μL of 50 mM NH 4 HCO 3 (pH 8.0) and treated with 50 μL of 25 mM NH 4 HCO 3 and 50% acetonitrile for 10 minutes. They were reduced with 10 mM dithiothreitol for 30 min and alkylated with 100 mM iodoacetamide for 15 min. The gel spots were then incubated with 13 μg/L trypsin at 37°C for 3 h. The digested peptides were extracted from the gel with 50 μl of 50% acetonitrile and 5% formic acid, dried in a Speed-Vac, and dissolved in 5 μL of 0.1% formic acid.
The peptides were loaded into a 150-μm ID Magic C 18 pre-column at 4 μL/min and separated in a 75-μm Magic C 18 analytical column (Michrom Biosciences, Auburn, CA). Peptides were eluted with a gradient of 0-40% acetonitrile in 0.1% formic acid at 0.3 μL/min over 60 min through an EASY n-LC nano-chromatography pump (Proxeon Biosystems). Eluted peptides were analyzed in an LTQ-Orbitrap hybrid ion trap-orbitrap mass spectrometer (Thermo Scientific) operated in a data-dependent acquisition mode [8] . MS was acquired at 60,000 FWHM resolution in the Fourier transform MS. MS/MS was carried out in the linear ion trap, and 6 MS/ MS scans were obtained per MS cycle.
All MS/MS data were analyzed with Mascot (Matrix Sciences), Sequest (Thermo Scientific), and X!Tandem (The GPM) using the Human UniProt database with digestion enzyme set to trypsin. Searches were carried out with a fragment ion mass tolerance of 0.60 Da and a parent ion tolerance of 10.0 ppm. Scaffold was used to validate MS/MS-based peptide and protein identifications. To ensure the highest quality of protein identification, only peptide identifications that exceeded 95% thresholds were accepted. Protein identifications were accepted if they contained more than two different identified peptides. Bioinformatics analyses and protein function searches were conducted using the UniProtKB database and NCBI BLAST [16] .
Western blotting
Proteins from 1D or 2D gels were transferred to PVDF membranes with Midi Transfer Packs in a TransBlot Turbo Transfer System (Bio-Rad). The membranes were blocked with 5% (m/v) BSA in phosphate buffed saline (PBS, pH 7.4) and 0.5% (v/v) Tween 20 at room temperature for 2 h, and then incubated with primary antibodies at room temperature for 2 h or at 4°C overnight. The primary antibodies were used at the following dilutions: patients' sera at 1:1,000, anti-maspin (clone G167-70, 554292; BD Pharmingen) at 1:500, anti-ANXA3 (sc-101885, Santa Cruz Biotechnology) at 1:500, anti-LAP3 (ab154809, Abcam) at 1:1,000, anti-PSA1 (ab109500, Abcam) at 1:1,000, and anti-β-actin at 1:10,000 dilution. The membranes were then incubated with secondary antibodies at room temperature for 1 h. The secondary antibodies used include goat anti-human IgG-HRP (horseradish peroxidase) (sc-2453, Santa Cruz Biotechnology) at 1:3,000 dilution, goat anti-mouse IgG-HRP (sc-2005) at 1:10,000 dilution, and goat anti-rabbit IgG-HRP (sc-2004) at 1:4,000 dilution. In between all steps, membranes were washed 3 times with PBS and 0.5% Tween 20. Membranes were developed with Clarity Western ECL Substrate (Bio-Rad). Membrane images were captured in a ChemiDoc MP imaging system (Bio-Rad).
The intensities of protein bands was analyzed with ImageJ software. The density (D) of a band was measured as Dpc (protein from cancer tissue) or Dpn (protein from normal tissue). The protein expression ratio between cancer and normal samples was calculated as the relative density RDp=Dpc/Dpn. The protein expression ratio (ER) was then calculated by normalizing the respective protein's ratio (RDp) with respect to the β-actin expression ratio (RDa) as ER=RDp/RDa [11] .
Immunohistochemistry (IHC)
Paraffin sections of 4 μm thickness were heated at 60°C overnight before staining. The slides were washed with TBS (pH 7.4), and antigens were retrieved by heating at 95°C for 8 min and boiling at 100°C for 1.5 h in Tris/borate/EDTA buffer (pH 8-8.5). Tissue sections were incubated at 37°C for 1 h with anti-maspin (1:400 dilution), anti-ANXA3 (1:100 dilution), anti-LAP3 (1:400 dilution), and anti-PSMA1 (1:400 dilution) in TBS containing 1% BSA. Antibody reaction was detected with www.impactjournals.com/oncotarget the UltraView Universal DAB Detection Kit (Ventana). The kit contains a cocktail of enzyme-labeled secondary antibodies that locate the bound primary antibody. The complex is then visualized with hydrogen peroxide substrate and 3, 3'-diaminobenzidine tetrahydrochloride (DAB) chromogen, which produces a dark brown precipitate that is readily detected by light microscopy. Cell nuclei were counterstained with Hematoxylin II and Bluing Reagent (Ventana). Immunohistochemical staining was scored according to the average stain intensity: 3 for dark brown color, 2 for medium brown, 1 for weak brown, and 0 for no staining.
CONCLUSIONS
In summary, this paper reports several new findings. We first developed an innovative immuno-proteomic method that uses antibodies in cancer patient sera to discover cancer-specific immunogens as cancer markers. We then used this approach to discover a set of cancerimmunogenic proteins in colon cancer (maspin, ANXA3, LAP3, and PSMA1) and showed that these proteins are overexpressed in the tumor, pointing to a possible abundance mechanism by which these proteins become immunogenic. Further research using larger cohorts spanning from early to late stages of disease as well as different treatment histories and outcomes will be needed to investigate whether the four proteins are correlated in overexpression, whether they contribute directly or indirectly to the pathobiology of the disease, and whether there are differences between primary and metastatic sites.
We hypothesize that tissue overexpression leads to immunologically abnormally visible proteins and thus induces specific serum antibodies against these abnormalities in the cancer patient. More generally, the totality of neoantigenic proteins in cancer (i.e., the "cancer antigen-ome") may be a promising avenue not only towards novel diagnostic serologic tests but also the basis for new targets of immunotherapeutic development. Our mass spectrometry-based immune-proteomic method of serum reactivity screening as developed in this paper should be a powerful tool for comprehensively characterizing such cancer autoantigen-omes.
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